Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects

• Published in: Vaccine Vol. 39; no. 47; pp. 6930 - 6935
• Main Authors: Chanthavanich, Pornthep, Versage, Eve, Van Twuijver, Esther, Hohenboken, Matthew
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 16.11.2021; Elsevier Limited
• Subjects: Adjuvants; Adjuvants, Immunologic; Adolescents; Age; Allergy and Immunology; Antibodies; Antibodies, Viral; Antibody Formation; Antibody response; Antigens; Avian flu; Cell culture; Cell Culture Techniques; Child; Children; Coronaviruses; COVID-19; cross immunity; Cross-protection; Dosage; Guillain-Barre syndrome; hemagglutination; Hemagglutination inhibition; Hemagglutination Inhibition Tests; Hemagglutinins; Humans; Immunogenicity; Influenza; Influenza A; Influenza A Virus, H5N1 Subtype; Influenza pandemic vaccine; Influenza Vaccines; Influenza, Human - prevention & control; MF59 adjuvant; pandemic; Pandemics; Pediatrics; Polysorbates; Safety; Seroconversion; Severe acute respiratory syndrome coronavirus 2; Squalene; Statistical methods; Teenagers; Vaccines; Variance analysis; Viruses; United Kingdom > UK; United States > US; Influenza pandemic vaccine; HI; MN; Immunogenicity; MF59 adjuvant; aH5N1c; Safety; Children; Adolescents; hemagglutination inhibition; microneutralization; MF59-adjuvanted, cell culture–based A/H5N1 influenza vaccine

•MF59-adjuvanted, cell-based flu vaccine (aH5N1c) may be advantageous in a pandemic.•aH5N1c elicited robust antibody responses to heterologous A/H5N1 strains.•Responses were higher when assayed with microneutralization than HI. Vaccines are the main prophylactic measure against pandemic influenza. A...